Creative Biolabs provides state-of-art services for any next-generation probiotics (NGPs) project with qualitative measurements. Our multidisciplinary team will provide flexible solutions for probiotic construction, safety, and toxicity evaluation. We are also specialized in improving current probiotics for the treatment of skin diseases, which can boost long-term efficacy and reduce the cost to a more affordable level.
Nowadays, a large group of skin diseases, including eczema, psoriasis, acne, rosacea, as well as vitiligo have been found in humans. The symptoms of the skin disease still vary greatly, some showing mild symptoms such as headaches and rashes, while others can be more severe and even life-threatening, including high fever, asphyxia. Till now, many factors have been found to contribute to the occurrence of various skin diseases. Among them, immune deficiency and genetic mutation are the most common reasons for 76% of skin disease cases.
For the treatment of skin diseases, many therapeutic agents and prescription drugs, such as antihistamines, antibiotics, and vitamins, have been broadly used in the clinic. Moreover, laser therapy and medicated creams have been also used in patients with skin diseases. Besides, a novel group of NGPs has been developed to prevent and treatment of various skin diseases both in preclinical trials and clinical trials. Comprehensive analysis of the genomic, metabolomics properties, safety, and efficacy of NGP candidates have rapidly attracted much more attention in recent studies.
Fig.1 Several types of skin diseases eczema and psoriasis. (Majumder, 2019)
In the past few years, many studies conducted on skin disease treatment suggest that NGPs should be powerful live biotherapeutic drugs for treating various skin diseases. As a result, Creative Biolabs has built up a wide spectrum of NGP discovery services to suit any requirement of our clients on the generation of novel NGP candidates. Recently, we have established a panel of assays and have equipped with many optimization technologies to enhance the performance of NGP candidates in clinical use. Up to now, we can offer a full range of beneficial bacteria-based NGPs development services based on the specific skin disease types, including but not limited to:
Atopic dermatitis (AD), a type of eczema, is a chronic skin inflammation that can cause skin itching, redness, and swelling, and cracking. Researchers have indicated that NGPs can effectively reduce the severity of allergies and AD by regulating the intestinal barrier and immune responses of the gut microbiome. Furthermore, some bacterial species and strains, such as Bacteroides spp. and Bifidobacterium spp. have proven the potential of being treated as live biotherapeutics drugs for preventing or treating AD patients. Additionally, the optimal dosing, suitable duration, prefect vehicles of NGP candidates have also been further evaluated and used to improve the safety and efficacy of AD therapy.
Psoriasis is a serious skin disease that can lead to abnormal cell amplification, skin red, and itchy. Psoriasis can grow anywhere, but typically affects the scalp, elbows, knees, and lower back. Pilot studies have revealed that the main cause of psoriasis is the dysregulation between effector T cells and regulatory T cells (Treg cells) in gut bacteria. NGPs play an important role in reducing inflammation by mediating our immune-regulating T-cells. They have been widely used for treating many skin disorders, especially for psoriasis. Several clinical trials using Lactobacillus spp.-based NGPs in psoriasis have confirmed the safety and efficacy of these NGPs in the reduction of psoriasis severity.
Netherton syndrome (NS) is a skin disorder that is usually associated with ichthyosiform erythroderma, trichorrhexis invaginata, as well as atopic diathesis. In recent years, due to the next-generation sequencing and bioinformatics platforms, a variety of potential NGP candidates have been developed and evaluated for NS treatment. For instance, certain strains of Lactobacillus spp. and Bifidobacterium spp. has been used as NGPs in a randomized, double-blind, placebo-controlled NS clinical trial. The results have shown that the diseased skin area and severity of psoriasis have decreased by 80% in 73.7% of patients in the NGP group and 32.8% in the control group, respectively (p < 0.05).
As the long-term pioneer as well as the market leader in the field of live biotherapeutics drug discovery, Creative Biolabs has established and commercialized a wide spectrum of NGP-based services for a wide variety of skin diseases treatment. With a variety of mature and comprehensive platforms, we are committed to conducting cutting-edge research projects, developing perfect NGP candidates, and meeting critical medical needs. If you are interested in our services, please contact us for more details.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.